Istvan Albert is a Research Professor of Bioinformatics at Pennsylvania State University , affiliated with the Department of Biochemistry and Molecular Biology . He leads the Bioinformatics Consulting Center and teaches BMMB 852: Applied Bioinformatics . Research Interests: Specializing in bioinformatics, large-scale biological data analysis, microarray and sequence analysis, scientific programming, algorithm development, and database-driven web development. His work spans gene ontology visualization , RNA-Seq analysis , and coronavirus research . Software Development: Created GeneScape for gene function visualization and bio for bioinformatics workflows. Maintains the Biostar Handbook series and the Biostars Q&A Forum , a leading bioinformatics resource.
Brinton Seashore-Ludlow is an Associate Professor at the Department of Oncology-Pathology, Karolinska Institute (KI), where he serves as team leader in Olli Kallioniemi's research group and group leader of the biology team at Chemical Biology Consortium Sweden (CBCS), SciLifeLab's national infrastructure. PhD in Biochemistry, KTH Royal Institute of Technology (2012) MSc in Chemical Biology, California Institute of Technology (2007) BA in Biochemistry, Macalester College (2001) His research bridges precision medicine and cancer biology through: Developing ex vivo patient-derived models for drug response prediction Molecular determinants of therapeutic efficacy Integration of high-content imaging with translational studies Focus on ovarian, breast, and pediatric cancers AI-driven analysis of drug sensitivity data Recent articles demonstrate: 3D tumor spheroid platforms for drug testing Epigenetic regulators in neuroblastoma Microfluidics for high-throughput assays Cancer-stroma interactions in treatment resistance Clinical validation of precision diagnostics He co-organizes the Overview Course in Cancer Drug Discovery at KI and leads projects funded by the Swedish Childhood Cancer Foundation.
Paras N. Prasad is a SUNY Distinguished Professor with joint appointments in Physics, Chemistry, Medicine, and Electrical Engineering at the University at Buffalo. He serves as Executive Director of the Institute for Lasers, Photonics and Biophotonics (ILPB), which he founded in 1999. Dr. Prasad holds the Samuel P. Capen Chair of Chemistry and has pioneered interdisciplinary research at the interface of photonics, nanotechnology, and biomedicine. Education: BSc, Bihar University, India (1964) MSc, Bihar University, India (1966) PhD, University of Pennsylvania (1971) Postdoctoral Fellow, University of Michigan (1971-74) Research Focus: Dr. Prasad's multidisciplinary research spans photonics, nanophotonics, and biophotonics, with emphasis on nonlinear optical processes in nanostructured materials. His work develops photonic technologies for information processing, medical imaging, and cancer therapy through nanoparticle-based drug delivery systems and diagnostic platforms. The ILPB laboratory features state-of-the-art instrumentation for advanced optical research. Publication Trends: Recent articles demonstrate strong focus on nanomedicine applications, particularly cancer theranostics using functional nanoparticles. Key themes include drug delivery systems, chiral photonic materials, bioimaging technologies, and nanoparticle synthesis techniques. The research consistently bridges fundamental materials science with translational medical applications. Honors and Awards: SPIE Gold Medal (2016) IEEE Photonics Society William Streifer Award (2021) American Chemical Society Peter Debye Award (2018) OSA Michael Feld Biophotonics Award (2017) IEEE Pioneer Award in Nanotechnology (2017) Fellow of National Academy of Inventors (2016) Guggenheim Fellowship (1997) Leadership: As ILPB Executive Director, Dr. Prasad leads multidisciplinary teams developing photonic technologies with applications in healthcare, energy, and communications. His research has generated nine spin-off companies, including Nanobiotix currently in advanced cancer therapy trials.
Vernita Gordon is an Associate Professor in the Department of Physics at the University of Texas at Austin (since 2018), previously serving as an Assistant Professor there from 2010 to 2018. She holds a Ph.D. in Physics from Harvard University (2003) and a B.Sc. in Physics and Mathematics from Vanderbilt University (1997). Her research focuses on understanding how physical characteristics like mechanics and spatial structure influence bacterial biofilms, particularly their interactions with the immune system and resistance to antibiotics. She has pioneered techniques such as laser trapping to manipulate biofilm structures and studies radiation effects on bacteria like Deinococcus radiodurans . Education: Ph.D. in Physics, Harvard University (2003) B.Sc. in Physics and Mathematics, Vanderbilt University (1997) Research Interests: Dr. Gordon’s work integrates biophysics, microbiology, and materials science to explore biofilm mechanics, bacterial mechanosensing, and radiation biology. Key areas include: How biofilm mechanics resist immune clearance and antibiotic treatment Role of surface stiffness and shear stress in biofilm initiation Radiation resistance mechanisms in Deinococcus radiodurans Development of tools like laser trapping to study biofilm structure Key Achievements: Recipient of the Elizabeth B. Gleeson Professorship (2023) and Texas Mindset Initiative Fellowship (2023) Provost’s Teaching Fellow (2020–2024) and multiple teaching awards Funded by NSF, NIH, and Cystic Fibrosis Foundation Published over 60 peer-reviewed articles, including in Nature , PNAS , and Biophysical Journal Advising & Outreach: She mentors graduate students in Physics, Microbiology, and Biomedical Engineering, emphasizing interdisciplinary training. Her group actively recruits undergraduates and collaborates with industry partners like Solvay and the College of Pharmacy. Outreach includes lesson plans for high school STEM education and community science initiatives. Labs & Collaborations: Her lab uses advanced microscopy, microrheology, and computational modeling. Key collaborations include work with the Contreras Lab (UT Austin Chemical Engineering) on radiation-resistant bacteria and the Raizen Lab (UT Austin Physics) on self-sterilizing surfaces.
Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.
Philip Boone, MD, PhD, is an Attending Physician in the Division of Genetics and Genomics at Boston Children's Hospital and an Instructor of Pediatrics at Harvard Medical School. He specializes in medical genetics with particular expertise in rare disorders, medical mysteries, deletion and duplication syndromes, and Cornelia de Lange syndrome. Dr. Boone sees patients at Boston Children's Brookline location (2 Brookline Place, 7th Floor) and provides comprehensive genetic care including diagnostics, counseling, and individualized management. Stanford University (Undergraduate, 2006) Baylor College of Medicine (Graduate & Medical School, 2013-2014) Boston Combined Residency Program (Internship & Residency, 2016-2020) Harvard Medical School Genetics Training Program (Fellowship, 2020) Dr. Boone's research focuses on neurodevelopmental disorders, chromatin regulation, and genetic diagnostics. His work spans from fundamental genetic mechanisms to clinical applications, with particular emphasis on cohesinopathies including Cornelia de Lange syndrome. He has contributed significantly to understanding genetic variants associated with growth disorders, developmental features, and structural chromosomal abnormalities. His research combines advanced genomic technologies with clinical insights to improve diagnosis and management of rare genetic conditions. Analysis of Dr. Boone's publication record reveals a strong focus on medical genetics with emphasis on neurodevelopmental disorders, chromatin regulation, and genetic diagnostics. His work spans basic research on gene function and regulation to clinical applications in rare disease diagnosis. A notable trend is his investigation of cohesin complex disorders, particularly SMC3 variants and their relationship to Cornelia de Lange syndrome. His publications demonstrate expertise in both traditional genetic analysis and cutting-edge genomic technologies including long-read sequencing and telomere-to-telomere assembly. Dr. Boone actively contributes to medical education through publications on genetic diagnostics and distance learning resources for medical genetics. He has co-authored educational materials that help advance the field's knowledge base and training capabilities. As an attending physician in the Division of Genetics and Genomics at Boston Children's Hospital and a research fellow in the Center for Genomic Medicine at Massachusetts General Hospital, Dr. Boone works within one of the largest pediatric genetics practices in the country. The division includes over 30 board-certified clinical geneticists, genetic counselors, dieticians, and nursing staff who provide comprehensive care for patients with both common and extremely rare genetic conditions.
Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.
Joe Stock is an Assistant Professor in Kinesiology at East Carolina University's College of Health and Human Performance. He operates the Human Performance Lab, focusing on cardiovascular wellness in aging and at-risk populations. B.S. in Exercise Science, Slippery Rock University M.S. in Health, Physical Activity and Chronic Disease, University of Pittsburgh Ph.D. in Kinesiology and Applied Physiology, University of Delaware His research examines aortic hemodynamics, vascular function, and lifestyle interventions through echocardiography, blood vessel ultrasound, and non-invasive blood pressure analysis. He explores sex differences in neurocardiovascular responses and salt sensitivity mechanisms. Recent publications demonstrate expertise in chronic kidney disease adaptations, exercise-induced vascular changes, and central sodium sensing. Collaborations span cardiovascular physiology, nephrology, and autonomic neuroscience. National Heart, Lung, and Blood Institute grant (2021-2023) University of Delaware Dissertation Fellowship (2019) University of Delaware Summer Doctoral Fellowship (2018) Professional service includes American Heart Association membership, ACSM regional committee work, and development of clinical exercise programs for renal patients. His work integrates applied physiology with translational medicine.
Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters
Daria Camilla Boffito is a Full Professor in the Department of Chemical Engineering at Polytechnique Montréal , holding the Tier-2 Canada Research Chair in Intensified Mechano-chemical Processes for Sustainable Biomass Conversion. Her research spans process intensification , catalysis , sonochemistry , photocatalysis , and metal extraction , with a focus on sustainability. Education: B.Sc. and Ph.D. in Industrial Chemistry from the University of Milan, M.Sc. in Industrial Chemistry and Management Current Research: Developing ultrasound-assisted extraction , CO2 conversion , and floating photocatalysts for wastewater treatment Collaborations: Works with Canadian and international companies on sustainable chemical processes Scientific Awards include the Canada Research Chair Tier-2 (2016-2021), NSERC Banting Postdoctoral Fellowship (2013-2016), and FRQNT PBEEE Postdoctoral Fellowship (2013-2016). Advising has seen 5 Ph.D. and 9 Master's students graduate. She leads the Engineering Process Intensification and Catalysis (EPIC) Laboratory and is a member of the Institut de génie biomédical .
Associate Professor LAM Yulin is affiliated with the National University of Singapore (NUS), specializing in bioorganic and medicinal chemistry with a focus on green synthesis methodologies. His research interests include developing anti-cancer, anti-inflammatory, and neurological agents, alongside creating recyclable catalysts for sustainable organic transformations. He holds a Ph.D. (1992) and B.Sc. (1987) from NUS, with prior research fellowships at the Institute of Molecular and Cell Biology (1994–1996) and The Scripps Research Institute (1992–1994). Teaching contributions include courses such as CM2122 Organic Chemistry, CM3225 Biomolecules, and CM5224 Emerging Concepts in Drug Discovery. His research highlights include synthesizing chondroitin sulfate analogs for molecular recognition via surface-enhanced Raman scattering (SERS) and developing fluorous boronic acid catalysts for amide bond formation under eco-friendly conditions. Research focuses on glycosaminoglycan structure-function relationships, novel mycobacterial inhibitors, and autophagy-inducing agents. His work bridges organic synthesis with biomedical applications, emphasizing sustainability and translational potential.
Xihong Lin is a Professor of Statistics at Harvard University and a Professor of Biostatistics at the Harvard T.H. Chan School of Public Health. She is a distinguished academic, holding membership in both the National Academy of Sciences and the National Academy of Medicine. Her research focuses on scalable statistical inference for big data, statistical machine learning, causal inference, and integrative data analysis, with applications in genomics, public health, and precision medicine. Lin’s work addresses challenges in analyzing large-scale genomic and multi-ancestry data, including methods for rare variant association testing, ancestry-adjusted sample analysis, and scalable computing frameworks. Her contributions span biobank studies (e.g., UK Biobank, TOPMed) and clinical applications in lung cancer, cardiovascular health, and smoking cessation. Her scientific awards reflect her leadership in statistical genetics and public health. Key research trends include leveraging single-cell sequencing for functional genomics, developing ensemble machine learning methods for health subtyping, and enhancing polygenic risk prediction across diverse populations. Lin’s methodologies prioritize interpretability and scalability, enabling impactful analyses of complex observational and genomic datasets. Awards: Member, National Academy of Sciences; Member, National Academy of Medicine Her grants and advising efforts focus on interdisciplinary collaborations, bridging statistics, AI, and domain sciences. Lin leads initiatives to improve genomic data management and ethical use of federated data (e.g., FADI framework). She is affiliated with labs advancing statistical genetics and cloud-based workflows (e.g., STAAR workflow).
Dr. Xuan Li is a British Heart Foundation (BHF) Senior Basic Science Research Fellow and Principal Investigator in Cardiovascular Health at the Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge. Her research focuses on microtubule dysfunction in inflammatory cardiovascular diseases, particularly investigating how microtubule regulation impacts inflammasome activation and cardiomyocyte contractility in heart failure and atherosclerosis. Her academic journey includes medical training in China, a CRUK-funded PhD in biochemistry at the University of Birmingham, postdoctoral research in microtubule cell biology as an MRC Career Development Fellow at the MRC-LMB Cambridge, and specialized cardiovascular medicine training at the University of Cambridge. She established her independent research group at Cambridge, pioneering multidisciplinary approaches to study microtubule function in cardiovascular cells. Dr. Li's research program centers on the role of microtubule-regulating kinases (particularly MARK4) in cardiovascular pathologies. Her group employs advanced methodologies including cardiovascular disease models (atherosclerosis, myocardial infarction, cardiomyopathy), primary cell culture of cardiomyocytes and immune cells, single-cell physiology using IonOptix systems, and cutting-edge microscopy techniques. Key discoveries include the identification of MARK4 as a critical regulator of inflammasome activation in atherosclerosis and microtubule detyrosination in ischemic heart failure. Her publication record demonstrates consistent focus on microtubule-cytoskeleton interactions in cardiovascular inflammation, with recent high-impact papers in Nature, Nature Communications, and Circulation Research revealing novel therapeutic targets for heart disease treatment through microtubule modulation. Scientific recognition includes: British Heart Foundation Senior Basic Science Research Fellowship MRC Career Development Fellowship Cancer Research UK PhD Studentship Dr. Li's group currently pursues four major research thrusts: elucidating microtubule dysfunction mechanisms in cardiovascular disease development, dissecting inflammation-microtubule interplay in pathogenesis, establishing human cardiomyocyte culture systems for microtubule studies, and translating basic findings into diagnostic and therapeutic applications for cardiovascular diseases. Her work bridges fundamental cell biology with clinical cardiology to develop innovative treatments targeting the microtubule cytoskeleton.
Gianmarco Pinton is an Associate Professor in the Department of Biomedical Engineering at the University of North Carolina at Chapel Hill. His research focuses on nonlinear ultrasound and mechanical wave propagation, with applications to medical imaging and therapy. He specializes in traumatic brain injury, shear shock waves, and ultrasound therapy. Ph.D., M.S., and B.S.E. in Biomedical Engineering/Physics from Duke University His lab develops physics and simulation tools for nonlinear wave propagation, aiming to create advanced diagnostic ultrasound methods. Key areas include traumatic brain injury, transcranial imaging, and therapeutic ultrasound. His recent work explores super-resolution imaging, brain motor circuits, and Alzheimer's disease vascular mapping using ultrasound. Article trends highlight innovations in transcranial ultrasound, super-resolution techniques, lung imaging, and neuromodulation. His publications address image degradation, contrast agents, and shear wave dynamics in neurological contexts.
Moira Whyte serves as Sir John Crofton Professor of Respiratory Medicine and Head of Edinburgh Medical School at the University of Edinburgh, while directing the MRC University of Edinburgh Centre for Inflammation Research. Her leadership spans clinical academia and major research initiatives focused on respiratory pathophysiology. Her educational background includes a 1st Class B.Sc. (1981), M.B., B.S. (1984), and Ph.D. (1993) from the University of London, complemented by professional qualifications: M.R.C.P. (1987), F.R.C.P. (1998), and F.Med.Sci. (2005) from the Academy of Medical Sciences. Whyte's research centers on neutrophil biology, macrophage function, and hypoxia signaling pathways in respiratory diseases. Her work explores how oxygen-sensing mechanisms like HIF pathways regulate immune cell function in COPD, pulmonary fibrosis, and bacterial infections, with particular focus on cellular metabolism and inflammation resolution. Analysis of her 15 most recent publications reveals consistent focus on neutrophil and macrophage biology within respiratory diseases, with growing emphasis on metabolic regulation of immune responses. Her work bridges basic science (using zebrafish models) with clinical applications, particularly in COPD and pulmonary fibrosis. Her scientific recognition includes: 2014 OBE for Services to Respiratory Medicine 2014 Foundation Fellow of the European Respiratory Society 2005 Fellow, Academy of Medical Sciences 2002 Tudor Edwards Lecturer of the Royal College of Physicians 1994 Wellcome Trust Advanced Fellowship 1989 MRC Clinical Training Fellowship Whyte directs substantial research funding, including a £6.4M Wellcome Trust Clinical PhD Programme (ECAT-Plus) and multiple grants investigating macrophage function in COPD, hypoxia pathways in pulmonary fibrosis, and neutrophilic inflammation regulation. Her collaborative approach is evident in multi-institutional projects like the EME-TIPAC study on pulmonary fibrosis. As Director of the MRC Centre for Inflammation Research, she leads a multidisciplinary team investigating fundamental mechanisms of inflammation across multiple disease contexts, with particular strength in respiratory immunology and translational applications.
